Circadian owns Vegenics
Thursday, 14 August, 2008
Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.
Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.
Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.
Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
